The Role of HER2 Alterations in Clinicopathological and Molecular Characteristics of Breast Cancer and HER2-targeted Therapies: a Comprehensive Review

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2022 Sep 29

PMID 36175719

Authors

Shafighe Asgari-Karchekani

Armin Aryannejad

Seied Asadollah Mousavi

Shirin Shahsavarhaghighi

Seyed Mohammad Tavangar

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) is the most common malignancy in women and one of the leading causes of cancer mortality, despite significant treatment advancements over the last decades. Human epidermal growth factor receptor-2 (HER2) is a member of the ERBB family of receptor tyrosine kinases which have long been known to mediate cancer cell growth and invasion through constitutive activation of oncogenic downstream signaling, such as PI3K/Akt/mTOR and MAPK. Overexpression/amplification of HER2 in various tumors, especially BC, offers the possible therapeutic potential for target therapies. HER2-targeted therapies, either with a combination of chemotherapy or through multi-anti-HER2 therapies without chemotherapy, have significantly improved the prognosis of HER2-positive tumors. In recent years, novel anti-HER2 agents and combination therapies have garnered much attention, especially for heavily treated advanced or metastatic BCs. HER2-positive BC is biologically a heterogeneous group depending on HER2 activation mechanisms, hormone receptor status, genome variations, tumor heterogeneity, and treatment resistance, which affect the treatment benefit and patients' outcomes. This review will discuss HER2 alternations (gene amplification or receptor overexpression) in BC, their correlation with clinicopathological characteristics and molecular characteristics, and HER2-based therapies in tumors with HER2 overexpression/amplification.

Citing Articles

Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients.

Abu Al Karsaneh O, Al Anber A, Alqudah M, Al-Mustafa S, AlMaaitah H, Sughayer M Diagn Pathol. 2023; 18(1):75.

PMID: 37340403 PMC: 10283286. DOI: 10.1186/s13000-023-01364-2.

How has the field of metastatic breast cancer in bones evolved over the past 22 years?.

Chen Y, Guo Z, He R, Huang Z, Luo J, Tang W J Bone Oncol. 2023; 40:100480.

PMID: 37251089 PMC: 10209145. DOI: 10.1016/j.jbo.2023.100480.

Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.

Shariaty Vaziri Z, Shafiee F, Akbari V Biotechnol Lett. 2023; 45(4):537-550.

PMID: 36807722 DOI: 10.1007/s10529-023-03360-4.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Baselga J . Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002; 7 Suppl 4:2-8. DOI: 10.1634/theoncologist.7-suppl_4-2. View

Guarneri V, Barbieri E, Dieci M, Piacentini F, Conte P . Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev. 2010; 36 Suppl 3:S62-6. DOI: 10.1016/S0305-7372(10)70022-0. View

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018; 142(11):1364-1382. DOI: 10.5858/arpa.2018-0902-SA. View

Dawood S, Broglio K, Buzdar A, Hortobagyi G, Giordano S . Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2009; 28(1):92-8. PMC: 2799236. DOI: 10.1200/JCO.2008.19.9844. View

Linggi B, Carpenter G . ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 2006; 16(12):649-56. DOI: 10.1016/j.tcb.2006.10.008. View

Stein R, Staros J . Evolutionary analysis of the ErbB receptor and ligand families. J Mol Evol. 2000; 50(5):397-412. DOI: 10.1007/s002390010043. View

10.

Citri A, Yarden Y . EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7(7):505-16. DOI: 10.1038/nrm1962. View

11.

Hendriks B, Opresko L, Wiley H, Lauffenburger D . Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem. 2003; 278(26):23343-51. DOI: 10.1074/jbc.M300477200. View

12.

Moasser M . The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007; 26(45):6469-87. PMC: 3021475. DOI: 10.1038/sj.onc.1210477. View

13.

Dey N, Williams C, Leyland-Jones B, De P . A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res. 2015; 7(4):733-50. PMC: 4455348. View

14.

Bose R, Kavuri S, Searleman A, Shen W, Shen D, Koboldt D . Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2012; 3(2):224-37. PMC: 3570596. DOI: 10.1158/2159-8290.CD-12-0349. View

15.

Mazieres J, Peters S, Lepage B, Cortot A, Barlesi F, Beau-Faller M . Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31(16):1997-2003. DOI: 10.1200/JCO.2012.45.6095. View

16.

Wang S, Narasanna A, Perez-Torres M, Xiang B, Wu F, Yang S . HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006; 10(1):25-38. DOI: 10.1016/j.ccr.2006.05.023. View

17.

Zabransky D, Yankaskas C, Cochran R, Wong H, Croessmann S, Chu D . HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015; 112(45):E6205-14. PMC: 4653184. DOI: 10.1073/pnas.1516853112. View

18.

Hainsworth J, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel D, Sweeney C . Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018; 36(6):536-542. DOI: 10.1200/JCO.2017.75.3780. View

19.

Bertos N, Park M . Breast cancer - one term, many entities?. J Clin Invest. 2011; 121(10):3789-96. PMC: 3195465. DOI: 10.1172/JCI57100. View

20.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View